Document Detail


Myeloperoxidase gene expression in infant leukemia: a Pediatric Oncology Group Study.
MedLine Citation:
PMID:  9638984     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A high incidence of co-expression of myeloid-associated antigens in infant B-precursor Acute Lymphocytic Leukemia (B-ALL) has been reported, but the significance of this finding is uncertain. To further assess myeloid differentiation and its prognostic significance in this disease, we investigated the frequency of myeloperoxidase (MPO) gene expression in the blast cells from 43 infants with B-ALL registered in a Pediatric Oncology Group (POG) Pilot Study for Treatment of Infant ALL, utilizing a molecular probe for detection of MPO messenger RNA (mRNA) by Northern blot hybridization and a monoclonal antibody to detect MPO-protein by immunohistochemical staining. Sufficient RNA for Northern blot was extracted from 32 bone marrow or blood samples. In two cases, MPO mRNA was determined by a reverse transcriptase-polymerase chain reaction assay and was negative in both cases. MPO-specific transcripts (MPO+) were present in 19 of 34 (56%) samples analyzed. Immunoreactive MPO protein was positive in 13 of the 20 (65%) patients studied. No correlation was found between MPO gene expression and clinical or laboratory features, karyotypic patterns or clinical outcome. The high frequency of MPO gene expression demonstrated in this study suggests that leukemogenic events in many cases of infant B-ALL appear to involve a pluripotent stem cell not yet fully committed to lymphoid differentiation.
Authors:
C S Alvarado; G E Austin; M J Borowitz; J J Shuster; A J Carroll; E D Austin; M Zhou; S R Zaki; J Pullen
Related Documents :
9801394 - Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide.
20442314 - Expression of oncogenic kinase bcr-abl impairs mitotic checkpoint and promotes aberrant...
22285684 - Interleukin 18 messenger rna and proil-18 protein expression in chorioamniotic membrane...
9357964 - Gas6, the ligand of axl and rse receptors, is expressed in hematopoietic tissue but lac...
24317064 - Transcription of st2a encoding a sulfotransferase family protein that is involved in ja...
18407964 - Evidence for sugar signalling in the regulation of asparagine synthetase gene expressed...
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Leukemia & lymphoma     Volume:  29     ISSN:  1042-8194     ISO Abbreviation:  Leuk. Lymphoma     Publication Date:  1998 Mar 
Date Detail:
Created Date:  1998-09-08     Completed Date:  1998-09-08     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9007422     Medline TA:  Leuk Lymphoma     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  145-60     Citation Subset:  IM    
Affiliation:
Emory University School of Medicine, Atlanta, Georgia, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies, Monoclonal
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Burkitt Lymphoma / drug therapy,  genetics*
DNA Primers
Female
Gene Expression Regulation, Enzymologic / physiology*
Gene Expression Regulation, Neoplastic / physiology*
Humans
Immunophenotyping
Infant
Infant, Newborn
Karyotyping
Male
Peroxidase / genetics*
Pilot Projects
Treatment Outcome
Grant Support
ID/Acronym/Agency:
CA-20549/CA/NCI NIH HHS; CA-28476/CA/NCI NIH HHS; CA-29139/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/DNA Primers; EC 1.11.1.7/Peroxidase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Expression of p53 predicts treatment failure in aggressive non-Hodgkin's lymphomas.
Next Document:  Residual leukemic cell counts in the bone marrow at the end point of intensive induction therapy may...